Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Protalix BioTherapeutics (PLX) EBIAT (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of EBIAT data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, EBIAT fell 27.22% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $5.4 million, up 156.15%, while the annual FY2024 figure was $2.9 million, 64.73% down from the prior year.
  • EBIAT reached $2.4 million in Q3 2025 per PLX's latest filing, up from $164000.0 in the prior quarter.
  • Across five years, EBIAT topped out at $19.3 million in Q2 2023 and bottomed at -$11.2 million in Q2 2021.
  • Average EBIAT over 5 years is -$1.7 million, with a median of -$3.6 million recorded in 2022.
  • Peak YoY movement for EBIAT: tumbled 2196.54% in 2021, then skyrocketed 462.56% in 2023.
  • A 5-year view of EBIAT shows it stood at -$6.7 million in 2021, then soared by 43.9% to -$3.7 million in 2022, then tumbled by 61.6% to -$6.0 million in 2023, then skyrocketed by 207.45% to $6.5 million in 2024, then plummeted by 63.74% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $2.4 million in Q3 2025, $164000.0 in Q2 2025, and -$3.6 million in Q1 2025.